Evidence map›Paper›PMID 35406518›Full record

ArticleCancers2022

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.

Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do Young Kim, Seong Gyu Hwang, Young Eun Chon, Hong Jae Chon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 5 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Lenvatinib, sintilimab combined interventional treatmentWorld journal of gastroenterology · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Beom Kyung KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.
Jaekyung CheonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.ORCID 0000-0001-8439-1739
Hyeyeong KimDepartment of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea.
Beodeul KangDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Yeonjung HaDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Do Young KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0002-8327-3439
Seong Gyu HwangDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.ORCID 0000-0002-6134-3651
Young Eun ChonDepartment of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.
Hong Jae ChonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea.ORCID 0000-0002-6979-5812
CHA University Bundang Medical Center · KRYonsei University · KRUlsan College · KR

Funding

National Research Foundation of Korea 2020R1C1C1010722
6 · The paper itself

Abstract

Lenvatinib (LENV) and atezolizumab/bevacizumab (ATE/BEV) have been approved as first-line regimens for the treatment of unresectable hepatocellular carcinoma (HCC). We aimed to compare their clinical efficacy and safety. Patients receiving ATE/BEV (n = 86) or LENV (n = 146) as first-line treatment were recruited from three academic hospitals in Korea. Overall survival (OS), progression-free survival (PFS), and radiological response were assessed according to the Response Evaluation Criteria in Solid Tumors. Clinical features of the two groups were balanced through propensity score (PS) matching with a 1:1 ratio and inverse probability of treatment weighting (IPTW) analyses. The median age was 62 years, with male predominance (83.6%). There was no significant difference in the objective response rate between the ATE/BEV and LENV groups (32.6% vs. 31.5%; p = 0.868). Neither median OS (not reached vs. 12.8 months; p = 0.357) nor PFS (5.7 vs. 6.0 months; p = 0.738) was different between ATE/BEV and LENV groups. PS-matched and IPTW analyses yielded comparable results in terms of OS and PFS (all p > 0.05). Grade ≥ 3 adverse events occurred in 42.8% and 21.9% of patients in the ATE/BEV and LENV groups, respectively (p = 0.141). The two first-line therapy regimens for unresectable HCC had comparable clinical efficacy and safety in real-world practice settings. Further studies with a larger sample size and longer follow-up are needed to validate these results.

Indexed as

atezolizumabbevacizumabcomparisonhepatocellular carcinomalenvatinib

Identifiers

PMID35406518
PMCPMC8996911
OpenAlexW4226277757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.